WB, IP, IF-IC, FC-FP
H M
Endogenous
55
Rabbit IgG
#Q99684
2672
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunofluorescence (Immunocytochemistry) | 1:800 - 1:3200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:800 - 1:1600 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human GFI1 protein.
Background
GFI1 and its homolog GFI1b are transcriptional repressors and important regulators of hematopoiesis (1). GFI1/GFI1b negatively regulate transcription by recruiting chromatin regulatory proteins including CoREST, the histone demethylase LSD1, and HDACs 1 and 2, which associate with the GFI1 proteins via their N-terminal SNAG repression domains (2,3). GFI1 is expressed in hematopoietic stem cells (HSCs), where it is necessary to restrict HSC proliferation and maintain functional integrity (4,5). It is also expressed in common lymphoid and myeloid progenitors, where it plays an essential role in lymphoid and granulo-monocytic differentiation (5,6). Indeed, GFI1 knockout mice show impaired granulocytic differentiation and develop severe neutropenia, causing them to die quickly due to bacterial infection (7,8). In contrast, GFI1b is necessary for erythroid and megakaryocytic development and differentiation, and inactivation of GFI1b in mice leads to embryonic lethality (9). Unsurprisingly, the GFI1 proteins are implicated in multiple blood disorders, and GFI1 specifically is considered to be a predictor and therapeutic target for acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) (10). A GFI1 variant protein caused by a point mutation (S36N) may also confer a disposition to AML and accelerate disease progression (11,12). Interestingly, GFI1 has also been described to be an oncogenic driver for certain subsets of Group 3 medulloblastomas (13,14).
- Duan, Z. and Horwitz, M. (2003) Hematology 8, 339-44.
- Saleque, S. et al. (2007) Mol Cell 27, 562-72.
- Beauchemin, H. and Möröy, T. (2020) Front Genet 11, 591099.
- Hock, H. et al. (2004) Nature 431, 1002-7.
- Zeng, H. et al. (2004) EMBO J 23, 4116-25.
- Möröy, T. et al. (2015) Blood 126, 2561-9.
- Karsunky, H. et al. (2002) Nat Genet 30, 295-300.
- Person, R.E. et al. (2003) Nat Genet 34, 308-12.
- Saleque, S. et al. (2002) Genes Dev 16, 301-6.
- Hönes, J.M. et al. (2016) Leukemia 30, 1237-45.
- Khandanpour, C. et al. (2010) Blood 115, 2462-72.
- Botezatu, L. et al. (2016) Exp Hematol 44, 713-726.e14.
- Vo, B.T. et al. (2017) Cell Rep 18, 2907-2917.
- Lee, C. et al. (2019) Nat Commun 10, 332.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.